CLDN18.2 CAR-T / Lyell Immunopharma - LARVOL DELTA

Therapeutic potential of IMPT-601, a Claudin18.2/TGF-β bispecific CAR, against gastric cancer (SITC 2024) - "Recent third-party Phase I clinical trials have reported efficacy of CLDN18.2 CAR T cells against GC/GEJC but improving CAR persistence in the tumor microenvironment (TME) remains a challenge. Animals treated with IMPT-601 maintained stable body weights throughout the study, suggesting IMPT-601 is well tolerated in these animals. Conclusions IMPT-601 is a potentially promising CAR T cell therapy candidate for the treatment of GC/GEJC by enabling the conversion of the immunosuppressive TGF-β into an activation signal, potentiating CAR T cells to accumulate in the immunosuppressive TME while retaining T cell fitness and reducing the frequency of regulatory T cells by dual targeting CLDN18.2 and TGF-β."

Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18 • TGFB1